Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway Inhibition

9 Dec 2022

Abstract excerpt

DNA double-strand breaks (DSBs) caused by platinum drugs are dangerous lesions that kill cancer cells in chemotherapy. Repair of DSB by homologous recombination (HR) and nonhomologous end joining (NHEJ) is frequently associated with platinum resistance in ovarian cancer. While the role of the HR pathway and HR-targeting strategy in platinum resistance is well studied, dissecting and targeting NHEJ machinery to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Microtubule and mitosis dynamics
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36551554
DOI: 10.3390/cancers14246068

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Platinum-Resistant Ovarian Cancer Is Vulnerable to the cJUN-XRCC4 Pathway InhibitionPMID 36551554Read ↗

Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancerSemantic proximity Read ↗

A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor ResistanceSemantic proximity Read ↗

Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cellsSemantic proximity Read ↗

Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapySemantic proximity Read ↗

Characterization of the nucleotide excision repair pathway and evaluation of compounds for overcoming the cisplatin resistance of non‑small cell lung cancer cell linesSemantic proximity Read ↗

Molecular mechanisms of cisplatin resistance in ovarian cancerSemantic proximity Read ↗

The role of XRCC4 in carcinogenesis and anticancer drug discovery.Semantic proximity Read ↗

Targeting RNF8 Effectively Reverse Cisplatin and Doxorubicin Resistance in Endometrial CancerSemantic proximity Read ↗

A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceSemantic proximity Read ↗

A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceSemantic proximity Read ↗

Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells.Semantic proximity Read ↗

β-Elemene enhances susceptibility to cisplatin in resistant ovarian carcinoma cells via downregulation of ERCC-1 and XIAP and inactivation of JNKSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.